Ana Melian‐Olivera

Ana Melian‐Olivera

Auto-generated profile, based on publicly available information

Ana Melian‐Olivera

Department of Dermatology, University Hospital Ramón y Cajal, Madrid, Spain; Trichology Unit, Grupo de Dermatología Pedro Jaén, Madrid, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2020 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
CGCristina Galvan
Cristina Galvan
ACA. Català
A. Català
GHG. Carretero Hernández
G. Carretero Hernández
PJPedro Rodriguez Jimenez
Pedro Rodriguez Jimenez
DFD. Fernández‐Nieto
D. Fernández‐Nieto
IGI. García‐Doval
I. García‐Doval
SummaryBackground. The cutaneous manifestations of COVID‐19 disease are poorly characterized.Objectives. To describe the cutaneous manifestations of COVID‐19 di

8 March 2021 in International Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
PBPatricia Burgos-Blasco
Patricia Burgos-Blasco
DFDiego Fernandez‐Nieto
Diego Fernandez‐Nieto
GSGerald Selda‐Enriquez
Gerald Selda‐Enriquez
AMAna Melian‐Olivera
Ana Melian‐Olivera
DPDarío De Perosanz-Lobo
Darío De Perosanz-Lobo
LALeticia Alonso‐Castro
Leticia Alonso‐Castro

19 February 2024 in Acta Dermato-Venereologica
Verified
Journal Article
Open access
PDF file
AMAna Melián-Olivera
Ana Melián-Olivera
ÓMÓscar Moreno-Arrones
Óscar Moreno-Arrones
PBPatricia Burgos-Blasco
Patricia Burgos-Blasco
ÁHÁngela Hermosa-Gelbard
Ángela Hermosa-Gelbard
PJPedro Jaén-Olasolo
Pedro Jaén-Olasolo
DSDavid Saceda-Corralo
David Saceda-Corralo
Folliculitis decalvans and lichen planopilaris phenotypic spectrum has been described as a form of cicatricial alopecia. The aim of this study is to describe the clinical and trichoscopic features and therapeutic management of this condition in a series of patients. A retrospective observational unicentre study was designed including patients with folliculitis decalvans and lichen planopilaris phenotypic spectrum confirmed with biopsy. A total of 31 patients (20 females) were included. The most common presentation was an isolated plaque of alopecia (61.3%) in the vertex. Trichoscopy revealed hair tufting with perifollicular white scaling in all cases. The duration of the condition was the only factor associated with large plaques (grade III) of alopecia (p = 0.026). The mean time to transition from the classic presentation of folliculitis decalvans to folliculitis decalvans and lichen planopilaris phenotypic spectrum was 5.2 years. The most frequently used treatments were topical steroids (80.6%), intralesional steroids (64.5%) and topical antibiotics (32.3%). Nine clinical relapses were detected after a mean time of 18 months (range 12–23 months). Folliculitis decalvans and lichen planopilaris phenotypic spectrum is an infrequent, but probably underdiagnosed, cicatricial alopecia. Treatment with anti-inflammatory drugs used for lichen planopilaris may be an adequate approach.

19 May 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
TRTuntas Rayinda
Tuntas Rayinda
SMSheila M. McSweeney
Sheila M. McSweeney
DFDavid Fenton
David Fenton
Catherine Margaret StefanatoCatherine Margaret Stefanato
Catherine Margaret Stefanato
MHMatthew Harries
Matthew Harries
CTChristos Tziotzios
Christos Tziotzios

16 June 2020 in Dermatologic Therapy
Verified
Journal Article
Open access
PDF file
ASAna Suarez‐Valle
Ana Suarez‐Valle
DFDiego Fernandez‐Nieto
Diego Fernandez‐Nieto
AMAna Melian‐Olivera
Ana Melian‐Olivera
MDMiguel Dominguez‐Santas
Miguel Dominguez‐Santas
BDBorja Diaz‐Guimaraens
Borja Diaz‐Guimaraens
JCJuan Jiménez Cauhé
Juan Jiménez Cauhé
Click on the article title to read more.

1 January 2023 in Dermatologic Therapy
Verified
Journal Article
Open access
PDF file
EAEva María Arias
Eva María Arias
GSGerald Selda-Enríquez
Gerald Selda-Enríquez
PBPatricia Burgos-Blasco
Patricia Burgos-Blasco
AMAna Melián-Olivera
Ana Melián-Olivera
SMSara Manzanares
Sara Manzanares
David Saceda CorraloDavid Saceda Corralo
David Saceda Corralo
Introduction. Androgenetic alopecia (AGA), the most common form of hair loss in women, is characterized by progressive hair thinning and loss of terminal hairs over frontal and parietal regions of the scalp. This study aimed to evaluate the efficacy of the nutritional supplement Pilopeptan® WOMAN 5αR (PPT5α) composed of specific plant extracts, vitamins, and minerals in women with initial to moderate AGA. Methods. This was a prospective, randomized, double‐blind, placebo‐controlled clinical trial study. Forty‐seven women (aged 25–59 years) with AGA grade I/II were randomized to daily receive PPT5α (n = 24) or placebo (n = 23), and the treatment safety, as well as the percentages of terminal hair in frontal and parietal areas from trichoscopic images, was assessed at 0, 3, and 6 months. Secondary outcomes included self‐assessed hair parameters and overall treatment satisfaction. Results. A total of 44 women completed the study. At 6 months, patients who received the nutritional supplement showed high percentages of terminal hair both in the frontal (77.6% vs 69.8%, p = 0.02) and parietal (77% vs 64.3%, p = 0.02) areas compared to the placebo group. Self‐assessed evaluation of hair parameters showed an improvement in the reduction of hair loss and hair thickness both at the 3‐month (p = 0.004 and p = 0.012) and 6‐month (p = 0.009 and p = 0.004) visits. At the 3 month visit, the intervention group also showed higher treatment satisfaction (p = 0.01). No significant adverse events were reported. Conclusion. These results evidence that the nutritional supplement PPT5α may be beneficial in preventing progression or even improving the condition of AGA in the early stages.